- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04467632
Circadian & Homeostatic Synchronization Effect on Waking Mobility in Parkinson's Disease (Synch Fit)
Circadian & Homeostatic Synchronization Effect on Waking Mobility in Parkinson's Disease: a Feasibility Study
Sleep benefit (SB) consists of a spontaneous, transient and inconsistent improvement of the mobility occurring on morning awakening in approximately 40% of Parkinson's disease (PD) patients, before taking the first morning dose of dopaminergic drugs.
The SB could represent a pathway for the development of new therapeutic strategies for motor symptoms in PD.
Being a seemingly unpredictable phenomenon and a great variability daily, inter- and intra-subject, the SB study requires multiple and repeated assessments of mobility for several days. An experimental home setting would be optimal for this purpose in terms of cost-effectiveness and patient acceptability.
In addition, since the extent and nature of SB have not been well characterized so far, and the magnitude of its variability is unknown, a reliable assessment method, independent of observers and situation, the SB is a requirement of further research in this area.
A recently developed technique combining machine learning algorithms with wireless portable sensors (accelerometers and gyroscopes) and software applications could be particularly promising for characterizing the complexity and multiplicity of SBs in. With this technique, repeated and multiple assessments of mobility can be performed in the homes of patients without the constant presence of a researcher.
This approach offers several advantages in terms of cost-effectiveness, feasibility and acceptability of study protocols by patients. It also improves the ecological validity of subjective and objective estimates of mobility in these patients.
The investigators chose to conduct this preliminary study on patients with PD rather than on healthy subjects, because SB is a phenomenon that has been described so far only in this population. Investigators also consider that the feasibility of the study will depend mainly on the patients' ability to move and the context of their own illness.
SB is a phenomenon induced by sleep. The propensity and timing of sleep depend on the coordinated interaction of the duration of the previous awakening (homeostatic process) and a circadian signal (circadian process). In order to better understand SB, it is necessary to study the reciprocal influences of the circadian and homeostatic process.
Investigators have devised a new paradigm to "shift" the circadian process phase around the homeostatic process, maintained under constant conditions, in order to observe the effect of the synchronism or desynchronization of these two processes on the awakening mobility of patients with an MP. This experimental approach was approved by Professor Aleksandar Videnovic (Harvard University School of Medicine, USA), opinion leader on circadian rhythmicity in the MP and scientific collaborator of this study.
As a first step, the investigators plan to implement a technology-assisted home-based methodology, to validate it in PD patients and to verify the logistic feasibility of this method-assisted approach in a small group of patients, in order to to be able to apply this paradigm in larger scientific projects.
Study Overview
Status
Conditions
Detailed Description
Parkinson's disease is a common neurodegenerative disorder touching 1.5% of the general population over 60 year-old and featuring impaired mobility with high impact on daily living and quality of life of the patients and their caregivers. Fourty percent of the patients with Parkinson's disease (PD) report inconstant, prominent, spontaneous, transitory improvement in mobility occurring on morning awakening, before taking their first morning dose of dopaminergic medications. This apparently unpredictable, highly variable, sleep-related phenomenon has been named "Sleep Benefit" (SB) by the scientists.
SB is a promising track to follow to develop novel therapeutic strategies for motor symptoms in PD. An innovative approach could be to induce modifications of mobility by influencing sleep regulation in PD patients in experimental settings.
Sleep propensity and timing depend on the coordinated interaction of the duration of preceding wakefulness (homeostatic component) and on a circadian signal (circadian component). Reciprocal interactions between homeostatic and circadian processes preside to internal synchrony of many physiological processes. We hypothesize SB to depend on serendipitous optimal synchronization between circadian and homeostatic process on morning awakening. As SB shows high day-to-day, inter- and intra-subject variability, studying SB requires multiple, repeated assessment of mobility during several days. A home-based experimental setting would be optimal for this purpose in terms of cost-effectiveness and acceptability by the patients. Moreover, considering that the range and nature of SB has not been well characterized so far, and that the amplitude of its variability is unknown, a reliable, observer- and situation-independent, reproducible assessment method of SB is a pivotal requirement for further research in this area.
A recently developed technique associating machine-learning algorithms with wireless wearable sensors (accelerometers and gyroscopes) and software applications might be particularly promising to characterize the complexity and multiplicity of SB in PD. Thanks to this technique, repeated, multiple assessments of mobility can be performed at patients' home without the constant presence of an investigator.
The working hypothesis of this study is that motor performance in PD patients improves on morning awakening when optimal synchrony between circadian and homeostatic regulation of sleep occurs. As first step, we envision to set up a home-based and technology-assisted methodology and to verify its scientific, technological and logistic feasibility.
The study will involve four work packages, for each of which specific endpoints are defined:
WP1: Definition of the logistics, setting, practices of the study procedures for home assessment;
WP2: Technological setup of:
- IMU wearable sensors
- SleepFit software application development
- light therapy (included sham light therapy)
- home polysomnography
- chronobiological assessments (distal-proximal skin body temperature gradient; Dim Light Melatonin Onset (DLMO) from salivary specimens;
Two work packages (3 and 4) will require patients inclusion and interventions on patients:
WP3: Validation of mobility assessment by wearable sensors: accuracy of machine learning algorithm to predict patients' motor status based on the MDS-UPDRS-III total score and on the 3.14 item (global clinical impression of mobility);
WP4: Testing in real-life conditions at patients' home in a small group of subjects.
Study Type
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Fort-de-France, France, 97200
- CHU de Martinique
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients > 18 years old;
- Patients affected with idiopathic PD, of both sexes;
- Hoehn and Yahr stage of 2 to 4 in the "on" state;
- Stable antiparkinsonian and/or psychotropic medications for at least 4 weeks prior to study screening;
- Reliable partner/caregiver to assist the patient during the study procedures;
- Affiliated person or beneficiary of a social security scheme;
- Free, informed and written consent signed by the participant and the investigator (at the latest on the day of inclusion and before any examination required by the research).
Exclusion Criteria:
- Patients < 18 years old;
- Atypical parkinsonian syndromes;
- Dementia;
- Treatment with extended-release dopaminergic drugs (excluding extended release levodopa given no later than 6 hours before the habitual bedtime);
- Use of hypno-sedative drugs or stimulants;
- Use of antidepressants unless on a stable dose for at least 3 months;
- Travel through 2 time zones within 90 days prior to study screening;
- Visual abnormalities that may interfere with light therapy, such as significant cataracts, narrow angle glaucoma or blindness;
- Any other medical condition potentially interfering with the assessment of mobility (e.g. limb amputation, post-stroke paralysis, severe osteo-articular condition);
- Any condition limiting the capability of the subject to understand the task to be performed at home by the patient himself (e.g. aphasia, oligophrenia);
- Severely altered physical and/or psychological health which, according to, the investigator, could affect the participant's compliance of the study;
- Inadequate housing conditions to perform home assessments;
- Patients refusing to participate in the study;
- Patients under legal guardianship or curatorship, pregnant and breastfeeding women, women of child-bearing age, persons in emergency situations;
- Persons participating in another research including a period of exclusion still in course and at any case < 1 month.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: OTHER
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Patients affected with idiopathic Parkinson Disease
|
The validity of the mobility assessment by IMU wearable sensors will be verified in Work Package 3. It will be defined as the accuracy of the machine learning algorithm to predict patients' motor status compared to the motor status assessed at clinical examination by means of the MDS-UPDRS-III scale and the Fit test. Prediction by machine learning will be compared with the MDS-UPDRS-III total score and with the 3.14 item (global clinical impression of mobility) of the same scale. The patients will be asked to perform all the motor tasks of the MDS-UPDRS-III scale and the finger tapping test (Fit test) with both hands wearing the IMU system. A subset of minimal motor tasks allowing good prediction of the patient's motor status by the machine learning algorithm will then be selected for Work Package 4. Baseline Phase B1: Observation phase: 1-week wrist actigraphy and sleep diary to assess habitual activity/rest routines. B2: Nocturnal sleep consolidation phase: 2 weeks: timed light exposure, constant sleep/wake routine and sleep restriction of 1 hour/night (based on habitual activity). Intervention phase
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Validation of the objective metrics of mobility
Time Frame: 12 months
|
The validity of the mobility assessment by Inertial Measurement Unit (IMU) wearable sensors will be verified. It will be defined as the accuracy of the machine learning algorithm to predict patients' motor status compared to the motor status assessed at clinical examination by means of the MDSUPDRS- III scale and the Fit test. Prediction by machine learning will be compared with the MDS-UPDRS-III total score and with the 3.14 item (global clinical impression of mobility) of the same scale. The patients will be asked to perform all the motor tasks of the MDS-UPDRS-III scale and the finger tapping test (Fit test) with both hands wearing the IMU system. |
12 months
|
Objective and subjective mobility
Time Frame: 12 months
|
Prediction of mobility by machine learning based on data from IMU wearable sensors; finger tapping test; VAS motor
|
12 months
|
Sleep and sleepiness
Time Frame: 12 months
|
Measured by sleep diary, SSS
|
12 months
|
Cognition (electronic Stroop test)
Time Frame: 12 months
|
12 months
|
|
Emotional state
Time Frame: 12 months
|
Measured by Visual Analog Scale(VAS) mood/anxiety
|
12 months
|
Fatigue
Time Frame: 12 months
|
Measured by VAS fatigue
|
12 months
|
Circadian phase
Time Frame: 12 months
|
Continuously for skin body temperature and repeated samples (every 30' for a total of 9 samples, in the evening around the bed time, for salivary DLMO
|
12 months
|
Sleep homeostasis (SWA)
Time Frame: 12 months
|
Calculated based on the EEG recording acquired by means of nocturnal portable polysomnography.
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Chronotype
Time Frame: 12 months
|
Measured by Horne & Ostberg Morningness/Eveningness Questionnaire (MEQ)
|
12 months
|
Sleep habits, sleep and wake-related symptoms, sleep quality
Time Frame: 12 months
|
Measured by Pittsburgh Sleep Quality Index (PSQI)
|
12 months
|
PD-specific sleep and wake-associated symptoms
Time Frame: 12 months
|
Measured by Parkinson's Disease Sleep Scale (PDSS-2)
|
12 months
|
Daytime symptoms of bad or insufficient sleep
Time Frame: 12 months
|
Measured by Epworth Sleepiness Scale (ESS) [96] and Fatigue Severity Scale (FSS)
|
12 months
|
Modification of mobility on morning awakening
Time Frame: 12 months
|
Measured by Sleep benefit questionnaire
|
12 months
|
Motor and non-motor symptoms of PD in daily living
Time Frame: 12 months
|
Measurded by MDS-UPDRS scale (parts I, II and IV)
|
12 months
|
Neuropsychological battery useful in idiopathic PD
Time Frame: 12 months
|
Measured by Mattis dementia rating scale (MDRS)
|
12 months
|
Mood
Time Frame: 12 months
|
Measured by Beck Depression Inventory (BDI)
|
12 months
|
Collaborators and Investigators
Investigators
- Principal Investigator: Pietro Luca RATTI, MD, CHU de Martinique
Study record dates
Study Major Dates
Study Start (ANTICIPATED)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 19_RIPH2-12
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Parkinson's Disease
-
Ohio State UniversityCompletedParkinson's Disease | Parkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease | Parkinson Disease, Idiopathic | Parkinson's Disease, IdiopathicUnited States
-
Assistance Publique - Hôpitaux de ParisFrance Parkinson AssociationUnknownHealthy Controls | Parkinson's Disease With LRRK2 Mutation | Parkinson's Disease Without LRRK2 MutationFrance
-
Merck Sharp & Dohme LLCCompletedParkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease
-
Universidade Federal de PernambucoCompletedParkinson's Disease.Brazil
-
University Hospital, GrenobleCompletedParkinson's Disease (Disorder)France
-
Neurocrine BiosciencesVoyager TherapeuticsCompletedBrain Diseases | Central Nervous System Diseases | Nervous System Diseases | Parkinson's Disease | Parkinsonian Disorders | Movement Disorders | Neurodegenerative Diseases | Idiopathic Parkinson's Disease | Basal Ganglia DiseaseUnited States
-
Second Affiliated Hospital of Soochow UniversityShanghai Regenelead Therapies Co., Ltd.RecruitingAdvanced Parkinson's DiseaseChina
-
AbbVieRecruitingParkinson's Disease (PD)Germany, Denmark, Spain, Israel
-
Beijing Tiantan HospitalRecruitingPD - Parkinson's DiseaseChina
-
Hubert FernandezRecruitingParkinson's Disease, IdiopathicUnited States
Clinical Trials on Validation of the mobility assessment by IMU wearable sensors
-
Istituto Nazionale di Ricovero e Cura per AnzianiCompletedPhysical Functional PerformanceItaly
-
Poznan University of Medical SciencesCompletedInfant DevelopmentPoland
-
Fitbit IncActive, not recruitingSleep ApneaUnited States, Ireland
-
University Medical Center GroningenUMC Utrecht; Stryker EndoscopyNot yet recruitingMalrotation | Intestinal Perforation | NEC | Atresia
-
French Society for Intensive CareCHU NantesCompletedTerminal Illness | Intensive Care Unit SyndromeFrance
-
Maastricht University Medical CenterZonMw: The Netherlands Organisation for Health Research and DevelopmentCompletedMemory Disorders | Delirium, Dementia, Amnestic, Cognitive DisordersNetherlands
-
Fondation Ophtalmologique Adolphe de RothschildRecruitingTrigeminal Neuralgia | Microvascular Decompression Surgery | Diffusion Tensor ImagingFrance
-
JhpiegoBotswana Ministry of HealthCompletedCervical Cancer | Human Papillomavirus InfectionBotswana
-
University Hospital, Basel, SwitzerlandCompletedTriage Risk StratificationSwitzerland